The strategic interaction between firms and formulary committees: Effects on the prices of new drugs

Journal of Health Economics

Volumn 27, Issue 2, 2008, Pages 377-404

  García Alonso, María D C ^a   García Mariñoso, Begoña ^b  

^a UNIVERSITY OF KENT   (United Kingdom)

^b CITY UNIVERSITY   (United Kingdom)

Author keywords

Drug formularies; Subsidies

Indexed keywords

COST-BENEFIT ANALYSIS; DECISION MAKING; DRUG DEVELOPMENT; HEALTH INSURANCE; PHARMACEUTICAL INDUSTRY; PUBLIC HEALTH; SUBSIDY SYSTEM;

ARTICLE; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG FORMULARY; HEALTH CARE COST; MATHEMATICAL COMPUTING; REIMBURSEMENT;

COST-BENEFIT ANALYSIS; DECISION MAKING, ORGANIZATIONAL; DRUG INDUSTRY; DRUGS, INVESTIGATIONAL; HUMANS; MODELS, ECONOMETRIC; PHARMACY AND THERAPEUTICS COMMITTEE; REIMBURSEMENT MECHANISMS; UNITED STATES;

EID: 40849094148     PISSN: 01676296     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhealeco.2007.06.003     Document Type: Article

References (12)

1. Bagwell K., and Riordan M.H. High and declining prices signal product quality. American Economic Review 81 (1991) 224-239
2. Borrell J.R. Drug price differentials caused by formularies and price caps. International Journal of the Economics of Business 10 1 (2003) 35-48
3. Cabrales, A., 2003. Pharmaceutical generics, vertical product differentiation and public policy, Working Paper UPF, 662.
4. Francis P.J. Dynamic epidemiology and the market for vaccinations. Journal of Public Economics 63 (1997) 383-406
5. Jelovac I. On the relationship between the negotiated price of pharmaceuticals and the patients co-payment (2002), mimeo University of Liege
6. Krieg R.G. The need for policy direction in the provision of care to the mentally ill: and interdisciplinary view. Journal of Socio-Economics 31 (2002) 105-113
7. Laux F.L. Addiction as a market failure: using rational addiction results to justify tobacco regulation. Journal of Health Economics 19 (2000) 421-437
8. Lu Z.J., and Comanor W.S. Strategic pricing of new pharmaceuticals. The Review of Economics and Statistics 80 1 (1998) 108-118
9. Olmstead T., and Zeckhauser R. The menu-setting problem and subsidized prices: drug formulary illustration. Journal of Health Economics 18 (1999) 523-550
10. Shapiro C. Optimal pricing of experience goods. Bell Journal of Economics 14 (1983) 497-507
11. Schmalensee R. Product differentiation advantages of pioneering brands. American Economic Review 72 (1982) 349-365
12. Scott Morton F. The strategic response by pharmaceutical firms to the Medicaid most-favoured-customer rules. The RAND Journal of Economics 28 2 (1997) 269-290